Medical/Pharmaceuticals
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of adva...
2026-07-10 16:53
1803
Professor Gang Shen's Orthodontic Team Publishes Third Consecutive Paper in the Journal of Aligner Orthodontics
SHANGHAI, July 8, 2026 /PRNewswire/ -- Professor Gang Shen, Chief GS R&D Scientist of Smartee Denti-Technology and Chief Orthodontist at Taikang Dental, together with his orthodontic team, has published a new researcharticle titled " Pathological Mandibular Retrusion: Causality and Orthodontic Int...
2026-07-09 17:55
2279
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective...
2026-07-09 17:28
2321
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PL...
2026-07-09 15:31
2065
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 8, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study,was published online in full in The New England Journal o...
2026-07-09 10:16
2230
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden th...
2026-07-09 09:13
1631
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The s...
2026-07-09 08:30
1570
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO , July 8, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, theBIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACRO...
2026-07-09 00:00
1812
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company...
2026-07-08 22:17
1903
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
* First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. * Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from development through commercialization. HA...
2026-07-08 22:00
2932
Seegene Launches Industry's First Global Million Clinical Study to Shape New Disease-Specific Testing Standards
* Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. * The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-...
2026-07-08 21:00
2286
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
* Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) * Included in the MSCI ESG Selection Indexes for the fourth consecutive year * Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Bi...
2026-07-08 15:15
2989
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine * Rentosertib represents a novel mec...
2026-07-07 21:43
3093
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capab...
2026-07-07 20:50
3566
Aureka Releases OpenDDE, an Open-Source Drug Discovery Engine Designed to Accelerate AI-Driven Therapeutic Discovery
All-atom biomolecular foundation model uses co-folding as the entry point to a scalable drug discovery engine; the release marks a concrete step toward advancing open scientific AI for future biomedical research that benefit patients. LAGUNA HILLS, Calif. and SHANGHAI, July 6, 2026 /PRNewswire/...
2026-07-07 08:00
3088
Nexsphere-F™ Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain
SEOUL, South Korea, July 6, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Radiology, the leading peer-reviewed journal in radiology and medical imaging with an impact factor of 17.6, has published cl...
2026-07-06 21:00
3430
Strategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics
SHANGHAI and GUANGZHOU, China, July 4, 2026 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. ("Sanyou Bio") and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. ("Baiyunshan Xihe") jointly announced the official signing of a strategic cooperation agreement. This partnership will focus ...
2026-07-04 23:25
6118
Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage
BASEL, Switzerland and SEOUL, South Korea, July 3, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 2nd that it introduced its data platform business at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland, highlighting the potential of its ring-type c...
2026-07-03 16:14
4256
Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence
CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Peng Wang as Chief Operating Officer (COO). Dr. Wang will be...
2026-07-03 09:36
3279
Neurophet Supplies 'Neurophet AQUA' to Raffles Medical in Singapore
* Providing Neurophet AQUA capable of analyzing brain atrophy and white matter degeneration… Securing meaningful clinical reference SEOUL, South Korea, July 2, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain...
2026-07-02 21:00
3673
Week's Top Stories
Most Reposted
InfoComm Asia 2026 - Asia's Super Connector for Professional AV - Takes Place Next Week in Bangkok
[Picked up by 295 media titles]
2026-07-07 09:00
PropertyGuru Group's 2025 Sustainability Report Reinforces its Commitment to More Resilient and Inclusive Urban Futures Across Southeast Asia
[Picked up by 289 media titles]
2026-07-08 12:09
A New Chapter Beckons: Four Seasons Resorts of Asia Celebrates Parenthood with Babymoon Offerings
[Picked up by 286 media titles]
2026-07-10 13:30
Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
[Picked up by 285 media titles]
2026-07-07 06:00
NCS launches enterprise AI platforms and products; deepens partnerships to accelerate AI-driven business transformation
[Picked up by 284 media titles]
2026-07-09 08:00Most Read
Founder Olive Tai Appointed Chairman of the Board of Synagistics; John Wu Appointed Chief Executive Officer as Company Enters Next Stage of AI and Digital Commerce Growth
2026-07-06 20:23
6832
Straits Forum | Taiwanese Youth Tells: Six Years Rooted in the Mainland - From Starting a Business to Ringing the Bell at HKEX
2026-07-04 16:29
6348
